Abstract
Unusual Treatment Response to Aflibercept, after Ranibizumab Treatment Failure, in Peripheral Exudative Haemorrhagic Retinopathy
Highlights
Peripheral exudative haemorrhagic retinopathy (PEHR) is a rare degenerative disease of the peripheral retina characterised by sub-retinal and sub-pigment epithelial haemorrhage and exudation out-width the macula
This case report highlights the utility of Aflibercept and a treat-and-extend regimen in the management of peripheral exudative haemorrhagic retinopathy (PEHR), refractive to Ranibizumab
The anti-Vascular Endothelial Growth Factor (VEGF) was altered to Aflibercept 2 mg in 0.05 ml intravitreal injection (Eylea®, Regeneron, Tarrytown, New York, USA and Bayer HealthCare, Berlin, Germany) every four weeks for 8 months
Summary
The authors report 79-year-old women with PEHR who had persistent treatment resistance to Ranibizumab, with rapid improvements once switched to Aflibercept. Post-intravitreal injection response was measured using visual acuity, subjective vision and anatomical macular optical coherence tomography findings
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Ophthalmology and Clinical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
